监狱环境中直接抗病毒药物治疗后丙型肝炎病毒再感染:SToP-C研究
在澳大利亚4所设有阿片类激动剂治疗但无针具交换项目的监狱中,2014至2019年纳入388例接受治疗的囚犯,161例有治疗后随访。随访145人年发现18例再感染,总再感染发生率12.5/100人年,近期注射吸毒且共用针具者升至28.7/100人年;调整分析中近期注射吸毒共用针具与再感染风险升高相关(aHR 4.74)。
要点
- 监狱内丙肝治疗后再感染发生率高,总体为12.5/100人年。
- 近期注射吸毒并共用针具者再感染发生率达28.7/100人年。
- 近期注射吸毒共用针具与再感染风险升高独立相关(aHR 4.74)。
核心结论
- 监狱内观察到高丙型肝炎病毒再感染率,治疗后监测和再治疗对限制再感染影响至关重要。
- 应考虑在监狱内实施高覆盖率的阿片类激动剂治疗和针具交换项目。
研究设计与样本
- SToP-C研究在澳大利亚4所监狱纳入2014至2019年间被监禁者,这些监狱设有阿片类激动剂治疗项目但无针具交换项目。
- 388例接受丙型肝炎病毒治疗者中,161例有治疗后随访并纳入分析(92%男性;中位年龄33岁;67%在监狱内有注射吸毒;中位随访9个月)。
- 接受治疗者每3至6个月随访一次,通过测序确认再感染,评估再感染发生率及相关因素。
主要发现
- 随访145人年期间识别18例再感染,总再感染发生率为12.5/100人年(95%CI:7.9-19.8)。
- 近期(过去一个月)注射吸毒者(n=71)中90%有接受性针具共用。
- 近期注射吸毒并共用针具者再感染发生率为28.7/100人年(95%CI:16.3-50.6)。
- 调整分析中,近期注射吸毒并共用针具与再感染风险升高相关(aHR 4.74,95%CI:1.33-16.80;P=.016)。
- 丙型肝炎病毒检测间隔每增加一个月与再感染风险降低相关(即检测到的机会;aHR 0.41,95%CI:0.26-0.64;P<.001)。
临床怎么用
- 作者认为治疗后监测和再治疗对限制再感染影响至关重要。
- 作者认为应考虑在监狱内实施高覆盖率的阿片类激动剂治疗和针具交换项目。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Injection drug use (IDU) following treatment for hepatitis C virus (HCV) infection may lead to reinfection, particularly if access to harm reduction services is suboptimal. This study assessed HCV reinfection risk following direct-acting antiviral therapy within Australian prisons that had opioid agonist therapy (OAT) programs but did not have needle and syringe programs (NSPs). METHODS: The Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C) study enrolled people incarcerated in 4 prisons between 2014 and 2019. Participants treated for HCV were followed every 3-6 months to identify reinfection (confirmed by sequencing). Reinfection incidence and associated factors were evaluated. RESULTS: Among 388 participants receiving treatment, 161 had available posttreatment follow-up and were included in analysis (92% male; median age, 33 years; 67% IDU in prison; median follow-up 9 months). Among those with recent (in the past month) IDU (n = 71), 90% had receptive needle/syringe sharing. During 145 person-years (PY) of follow-up, 18 cases of reinfection were identified. Reinfection incidence was 12.5/100 PY (95% confidence interval [CI]: 7.9-19.8) overall, increasing to 28.7/100 PY (95% CI: 16.3-50.6) among those with recent IDU and needle/syringe sharing. In adjusted analysis, recent IDU with needle/syringe sharing was associated with increased reinfection risk (adjusted hazard ratio [aHR], 4.74 [95% CI: 1.33-16.80]; P = .016) and longer HCV testing interval with decreased risk (ie, chance of detection; aHR, 0.41 per each month increase [95% CI: .26-.64]; P < .001). CONCLUSIONS: A high rate of HCV reinfection was observed within prison. Posttreatment surveillance and retreatment are -essential to limit the impact of reinfection. High-coverage OAT and NSPs should be considered within prisons. CLINICAL TRIALS REGISTRATION: NCT02064049.
引用
- Carson JM, Dore GJ, Lloyd AR, et al. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clin Infect Dis. 2022. PMID: 35362522. doi:10.1093/cid/ciac246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。